Core Viewpoint - The company TianKang (301263.SZ) has received a notice of acceptance for the production registration application of Indobufen Tablets from the National Medical Products Administration of China, indicating progress in bringing this drug to market [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application for Indobufen Tablets [1] - The National Medical Products Administration has reviewed and accepted the application for the drug, which is a significant step towards its market launch [1] Group 2: Product Information - Indobufen Tablets are classified as platelet aggregation inhibitors, which work by reversibly inhibiting cyclooxygenase and various inducers to reduce the risk of thrombosis [1] - The drug is intended for use in ischemic cardiovascular diseases and ischemic cerebrovascular diseases caused by arteriosclerosis, as well as for preventing thrombosis during hemodialysis [1]
泰恩康(301263.SZ)：吲哚布芬片境内生产药品注册上市许可申请获受理